Search Results
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
a long-term vision, free of influence from fiduciary responsibilities. Servier invests close to 20% of revenue from brand-name medicines in R&D each year. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its
More news about: Servier Pharmaceuticals
May 31, 2026, 16:32 ET Creality Rayakan 12 Tahun Inovasi dengan KliTek™ dan Ekspansi Ekosistem Berbasis AI
baru dengan desain portabel dan kemampuan tangkapan digital (digital capture) yang sangat akurat.Sistem Daur Ulang Filamen M1 & R1 — platform daur ulang material yang membantu pengguna mengolah kembali limbah material menjadi filamen khusus, serta mendukung proses manufaktur
More news about: Creality
May 31, 2026, 14:09 ET EQT sets target fund size for EQT Infrastructure VII at EUR 21 billion
https://news.cision.com/eqt/r/eqt-sets-target-fund-size-for-eqt-infrastructure-vii-at-eur-21-billion,c4355536The following files are available for download:
More news about: EQT
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform,
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
metastatic head and neck squamous cell carcinoma (R/M HNSCC). The study includes five cohorts exploring RYBREVANT FASPRO™ across different treatment settings and regimens.Cohort 1 evaluated RYBREVANT FASPRO™ as monotherapy in patients with R/M HNSCC who had received prior platinum-based
More news about: Johnson & Johnson
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html 12 Napodano G, Ferro M, Sanseverino R. High-risk prostate cancer: A very challenging disease in the field of uro-oncology. Diagnostics (Basel). 202126;11(3):400. doi:10.3390/diagnostics11030400
More news about: Johnson & Johnson
May 31, 2026, 05:30 ET MARSTEK Unveils the New VENUS Family, Expanding Plug-in Batteries into a New Era of Home Energy Storage
MARSTEK as it continues accelerating the evolution of plug-in energy storage solutions for European households. Guests toured MARSTEK's Battery R&D Institute, R&D Center, Testing Laboratory, Experimental Center and production lines, including the VENUS E Gen 3.0 production line, inverter manufacturing
More news about: Marstek Energy Co., Limited
May 31, 2026, 05:30 ET MARSTEK dévoile la nouvelle gamme VENUS et fait entrer les batteries plug-in dans une nouvelle ère du stockage d'énergie résidentiel
l'entreprise continue d'accélérer l'évolution des solutions de stockage d'énergie plug‑in pour les foyers européens. Les invités ont visité le laboratoire de R&D sur les batteries, le laboratoire d'essais de fiabilité ainsi que les lignes de production automatisées de MARSTEK, dont la chaîne de production du
More news about: Marstek Energy Co., Limited
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
months.Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals
More news about: Dizal Pharmaceutical
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
by MSD.About Kelun-BiotechKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major
More news about: Kelun-Biotech
May 30, 2026, 16:57 ET Creality đánh dấu cột mốc 12 năm với KliTek™ và mở rộng hệ sinh thái được hỗ trợ bởi AI
minh và khả năng thu nhận dữ liệu số có độ chính xác cao dành cho nhà sáng tạo và người dùng chuyên nghiệp.Hệ thống tái chế sợi nhựa M1 và R1 — Nền tảng tái chế và tái tạo vật liệu cho phép người dùng tái chế vật liệu thải và sản xuất sợi nhựa tùy chỉnh, hỗ trợ quy trình sản xuất bền vững
More news about: Creality
May 30, 2026, 16:52 ET 크리얼리티, KliTek™와 AI 기반 생태계 확장으로 12주년 맞아
레이저 플랫폼이다.Pika & Sermoon P1 Scanner — 휴대형 설계, 지능형 이미징, 고정밀 디지털 캡처 기능을 결합한 차세대 스캐닝 솔루션으로, 크리에이터와 전문 사용자를 위해 설계됐다.M1 & R1 Filament Recycling System — 사용자가 폐기 소재를 재활용하고 맞춤형 필라멘트를 생산할 수 있도록 하는 소재 재활용 및 재생 플랫폼으로, 더욱 지속 가능한 제조 워크플로를 지원한다.제품에서 완전한 AI 기반 생태계로
More news about: Creality
May 30, 2026, 15:15 ET EngineAI Resmikan Pabrik Cerdas di Shenzhen, Robot Humanoid T800 Mulai Dikirim secara Massal
massal, bergerak dari nol menuju skala penuh."Empat Pilar Strategis yang Menjaga KualitasDidukung kemampuan riset dan pengembangan (R&D) secara independen, EngineAI mengembangkan sistem penjaminan mutu yang bertumpu pada empat pilar utama:Kualitas rantai pasok
More news about: EngineAI
May 30, 2026, 11:35 ET /C O R R E C T I O N -- Hyundai Motor America/
headquarters in California, the Hyundai Motor Manufacturing Alabama assembly plant, the all-new Hyundai Motor Group Metaplant America, several cutting-edge R&D facilities and more than 855 independent dealers. These operations are part of Hyundai Motor Group, which is
More news about: Hyundai Motor America
May 30, 2026, 08:05 ET ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
role of GammaTile in the treatment of brain tumors: a technical and clinical overview. J Neurooncol. 2024;166:203-212.Kutuk T, Kotecha R, Herrera R, et al. Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis resection cavities.
More news about: GT Medical Technologies
May 30, 2026, 08:00 ET The Rosen Law Firm, P.A. Continues to Remind Investors of the Proposed Class Action Settlement on Behalf of Purchasers of Sun Communities, Inc. Publicly-Traded Common Stock - SUI
Lead Counsel Jonathan R. HorneThe Rosen Law Firm, P.A.275 Madison Ave40th FloorNew York, NY 10016
More news about: The Rosen Law Firm, P.A.
May 30, 2026, 06:29 ET EngineAI ra mắt cơ sở sản xuất thông minh tại Thâm Quyến, lô robot hình người T800 đầu tiên xuất xưởng, bắt đầu giao hàng quy mô lớn
và từ con số 0 tới quy mô lớn".Bốn trụ cột chiến lược bảo đảm chất lượng toàn diệnTận dụng năng lực nghiên cứu và phát triển (R&D) toàn diện độc lập, EngineAI đã thiết lập một khuôn khổ bảo đảm chất lượng nghiêm ngặt được xây dựng dựa trên bốn trụ cột chiến lược:Kiểm
More news about: EngineAI
May 30, 2026, 04:50 ET Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
https://news.cision.com/bioarctic/r/number-of-shares-and-votes-in-bioarctic-ab--publ--as-of-may-29--2026,c4355174The following files are available for download:
More news about: BioArctic
May 30, 2026, 04:31 ET Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
https://news.cision.com/bioarctic/r/number-of-shares-and-votes-in-bioarctic-ab--publ--as-of-may-29--2026,c4355174The following files are available for download:
More news about: BioArctic
May 30, 2026, 04:25 ET Number of shares and votes in EQT
https://news.cision.com/eqt/r/number-of-shares-and-votes-in-eqt,c4354525The following files are available for download:
More news about: EQT
May 30, 2026, 04:14 ET Replenish Nutrients: Market Has Yet to Price in the H2 2026 Capacity and Licensing Inflection
https://news.cision.com/replenish-nutrients/r/replenish-nutrients--market-has-yet-to-price-in-the-h2-2026-capacity-and-licensing-inflection,c4355421
More news about: Replenish Nutrients
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
by MSD.About Kelun-BiotechKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major
More news about: Kelun-Biotech
May 29, 2026, 23:29 ET Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
NSCLC.About Kelun-BiotechKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major
More news about: Kelun-Biotech
